Who are DW51211's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Allr3, PF-06882961 (Cohorts 1 and 2), Entecavir+Fuzheng Huayu+TCM Granule, D-Col Personal Hygiene Convenience Kit, ECx1, PF-07104091 monotherapy dose expansion (ovarian).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dw51211.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

DW51211 — Competitive Intelligence Brief

DW51211 (DW51211) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

phase 3 molecular target Small molecule Live · refreshed every 30 min

Target snapshot

DW51211 (DW51211) — Daewon Pharmaceutical Co., Ltd.. DW51211 is a small molecule drug that targets the molecular target.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DW51211 TARGET	DW51211	Daewon Pharmaceutical Co., Ltd.	phase 3		molecular target
Allr3	allr3	Pfizer	marketed	The pharmacological class of ALLR3 is not specified.	The molecular target of ALLR3 is not specified.
PF-06882961 (Cohorts 1 and 2)	pf-06882961-cohorts-1-and-2	Pfizer	marketed	pharmacological class	molecular target
Entecavir+Fuzheng Huayu+TCM Granule	Entecavir+Fuzheng Huayu+TCM Granule	ShuGuang Hospital	marketed	Nucleoside reverse transcriptase inhibitor + Traditional Chinese Medicine herbal combination	HBV reverse transcriptase (entecavir component); multiple herbal constituents with unclear specific molecular targets
D-Col Personal Hygiene Convenience Kit	col	Pfizer	marketed	not well-documented	various molecular targets
ECx1	ECx1	Oregon Health and Science University	marketed	small molecule	ECx1's molecular target is unknown
PF-07104091 monotherapy dose expansion (ovarian)	pf-07104091-monotherapy-dose-expansion-ovarian	Pfizer	marketed	small molecule	[insert molecular target]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DW51211 — Competitive Intelligence Brief. https://druglandscape.com/ci/dw51211. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab